The involvement of miRNAs in CYP450 gene expression: A brief review of the literature
| dc.authorid | 0000-0003-2216-4084 | |
| dc.contributor.author | Tezcan, Tuğba | |
| dc.contributor.author | Özkan-Kotiloğlu, Selin | |
| dc.contributor.author | Kaya-Akyüzlü, Dilek | |
| dc.date.accessioned | 2023-01-03T14:06:27Z | |
| dc.date.available | 2023-01-03T14:06:27Z | |
| dc.date.issued | 2022 | en_US |
| dc.department | Kapadokya Üniversitesi, Kapadokya Meslek Yüksekokulu, Tıbbi Laboratuvar Teknikleri Bölümü | |
| dc.description.abstract | Drug biotransformation is a critical process in metabolic elimination of drugs. It occurs mainly in the liver as well as in other tissues such as kidney and small intestine and consists of three stages: Phase I, Phase II and Phase III. Drugs are converted to a more polar and hydrophilic metabolites during Phase I and Phase II, which are excreted by a variety of membrane transporters such as P-glycoprotein and Multidrug Resistance Protein 1 in Phase III. Cytochrome P450 enzyme isoforms achieve 80% of Phase I metabolism. It is well described that there is inter-individual drug response variability such as adverse drug reactions or reduced drug efficacy and that genetic variation within the sequence of biotransformation-related genes affects these different therapeutic outcomes observed between individuals. However, genetic factors cannot completely explain inter-individual differences. Recent studies have shown that epigenetic factors such as histone modification, DNA methylation and non-coding miRNAs heavily influence drug biotransformation through post-transcriptional regulation of metabolism gene expression. It is important to understand the causes of alterations in drug metabolism since varied biotransformation may lead to adverse drug effects or a loss of efficacy. Therefore, in this review, the effects of miRNAs in CYP450 gene expression will be discussed briefly in the light of recent studies. | |
| dc.identifier.endpage | 254 | en_US |
| dc.identifier.issue | 2 | en_US |
| dc.identifier.startpage | 243 | en_US |
| dc.identifier.uri | https://jrespharm.com/content.php?id=75 | |
| dc.identifier.uri | https://doi.org/10.29228/jrp.122 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12695/1961 | |
| dc.identifier.volume | 26 | en_US |
| dc.institutionauthor | Tezcan, Tuğba | |
| dc.language.iso | en | |
| dc.publisher | Journal of Research Pharmacy | |
| dc.relation.publicationcategory | Makale - Uluslararası - Editör Denetimli Dergi | |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | miRNA | |
| dc.subject | CYP450 | |
| dc.subject | Gene Expression | |
| dc.subject | Epigenetics | |
| dc.subject | Inter-individual difference | |
| dc.title | The involvement of miRNAs in CYP450 gene expression: A brief review of the literature | |
| dc.type | Article |
